Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 14/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859357 | 0.99 | RXFP1 (0.70) | RXFP1ALDH1A1TSHRMAPK1ABCC1 | |
| SCHEMBL6922057 | 0.94 | RXFP1 (0.64) | RXFP1ALDH1A1TSHRMAPK1ABCC1 | |
| SCHEMBL18292476 | 0.84 | RXFP1 (1.00) | RXFP1ALDH1A1TSHRMAPK1ABCC1 | |
| SCHEMBL6920587 | 0.77 | ABCC1 (0.79) | ABCC1ABCG2 | |
| SCHEMBL6917425 | 0.76 | ABCC1 (1.00) | RXFP1ABCC1ABCG2 | |
| SCHEMBL6920314 | 0.76 | ABCC1 (1.00) | RXFP1ABCC1ABCG2 | |
| SCHEMBL6922076 | 0.74 | ABCC1 (0.77) | RXFP1ABCC1ABCG2 | |
| SCHEMBL7118898 | 0.74 | HTT (0.97) | RXFP1ALDH1A1TSHRMAPK1ABCC1 | |
| SCHEMBL6920444 | 0.74 | HTT (0.97) | RXFP1ALDH1A1TSHRMAPK1ABCC1 | |
| SCHEMBL7119641 | 0.74 | HTT (0.71) | RXFP1ALDH1A1TSHRMAPK1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| WO-2004065389-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE | XENOVA LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | RXFP1 3176/4885ALDH1A1 2638/4885TSHR 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.